Global Blood Therapeutics (NASDAQ:GBT) is scheduled to post its quarterly earnings results after the market closes on Monday, March 12th. Analysts expect Global Blood Therapeutics to post earnings of ($0.72) per share for the quarter.

Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($0.94) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.22). On average, analysts expect Global Blood Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Global Blood Therapeutics (NASDAQ:GBT) opened at $60.95 on Monday. Global Blood Therapeutics has a 12-month low of $24.02 and a 12-month high of $68.05. The company has a market capitalization of $2,800.00 and a price-to-earnings ratio of -22.16.

In related news, insider Peter Radovich sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $50.00, for a total value of $750,000.00. Following the sale, the insider now directly owns 17,684 shares of the company’s stock, valued at $884,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Perceptive Advisors Llc acquired 175,000 shares of Global Blood Therapeutics stock in a transaction that occurred on Tuesday, December 19th. The stock was acquired at an average cost of $38.00 per share, for a total transaction of $6,650,000.00. The disclosure for this purchase can be found here. Insiders sold 54,812 shares of company stock worth $3,053,578 over the last ninety days. 5.30% of the stock is currently owned by insiders.

A number of research analysts recently commented on the company. ValuEngine cut Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. BidaskClub cut Global Blood Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 20th. Janney Montgomery Scott assumed coverage on Global Blood Therapeutics in a research report on Tuesday, February 13th. They issued a “buy” rating and a $75.00 price target on the stock. William Blair restated a “buy” rating on shares of Global Blood Therapeutics in a research report on Wednesday, February 28th. Finally, Zacks Investment Research upgraded Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 6th. Two equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $68.64.

COPYRIGHT VIOLATION NOTICE: “Global Blood Therapeutics (GBT) Scheduled to Post Earnings on Monday” was originally posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Earnings History for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with's FREE daily email newsletter.